{"id":32704,"date":"2025-04-29T21:06:42","date_gmt":"2025-04-29T13:06:42","guid":{"rendered":"https:\/\/flcube.com\/?p=32704"},"modified":"2025-04-29T21:06:42","modified_gmt":"2025-04-29T13:06:42","slug":"innovent-biologics-expands-clinical-partnership-with-immvirx-to-include-hepatocellular-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=32704","title":{"rendered":"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma"},"content":{"rendered":"\n

China-based Innovent Biologics Inc. (HKG: 1801<\/a>) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX’s investigational oncolytic virus product IVX037 combined with Innovent’s Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.<\/p>\n\n\n\n

Expanded Partnership Details<\/strong>
The ongoing Phase Ib study, which is currently assessing the anti-tumor activity and tolerability of the combination therapy in advanced colorectal cancer, ovarian cancer, and gastric cancer, has been enrolling patients from 7 centers across Australia. According to the latest agreement, the study will add 15 liver cancer patients and is expected to include new study centers.<\/p>\n\n\n\n

Initial Partnership and Background<\/strong>
Innovent and ImmVirX initially partnered in February 2022 to jointly investigate the combination therapy in clinical trials targeting advanced colorectal, ovarian, and gastric cancers. The expanded partnership now includes the evaluation of the combination in hepatocellular carcinoma, further broadening the scope of their collaborative efforts.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and…<\/p>\n","protected":false},"author":1,"featured_media":32705,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,910,198],"class_list":["post-32704","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-hkg-1801","tag-innovent-biologics"],"yoast_head":"\nInnovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX\u2019s investigational oncolytic virus product IVX037 combined with Innovent's Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=32704\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma\" \/>\n<meta property=\"og:description\" content=\"China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX\u2019s investigational oncolytic virus product IVX037 combined with Innovent's Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=32704\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-29T13:06:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2916.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma\",\"datePublished\":\"2025-04-29T13:06:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704\"},\"wordCount\":179,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2916.webp\",\"keywords\":[\"Cancer\",\"HKG: 1801\",\"Innovent Biologics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32704#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=32704\",\"name\":\"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2916.webp\",\"datePublished\":\"2025-04-29T13:06:42+00:00\",\"description\":\"China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX\u2019s investigational oncolytic virus product IVX037 combined with Innovent's Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=32704\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2916.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/2916.webp\",\"width\":1080,\"height\":608,\"caption\":\"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=32704#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma - Insight, China's Pharmaceutical Industry","description":"China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX\u2019s investigational oncolytic virus product IVX037 combined with Innovent's Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=32704","og_locale":"en_US","og_type":"article","og_title":"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma","og_description":"China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX\u2019s investigational oncolytic virus product IVX037 combined with Innovent's Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.","og_url":"https:\/\/flcube.com\/?p=32704","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-04-29T13:06:42+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2916.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=32704#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=32704"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma","datePublished":"2025-04-29T13:06:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=32704"},"wordCount":179,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=32704#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2916.webp","keywords":["Cancer","HKG: 1801","Innovent Biologics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=32704#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=32704","url":"https:\/\/flcube.com\/?p=32704","name":"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=32704#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=32704#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2916.webp","datePublished":"2025-04-29T13:06:42+00:00","description":"China-based Innovent Biologics Inc. (HKG: 1801) announced the expansion of its existing clinical cooperation and supply agreement with Australian partner ImmVirX Pty Ltd to include the hepatocellular carcinoma (HCC) field. This collaboration aims to assess the therapeutic effects of ImmVirX\u2019s investigational oncolytic virus product IVX037 combined with Innovent's Tyvyt (sintilimab), a programmed death-1 (PD-1) inhibitor, in HCC.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=32704#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=32704"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=32704#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2916.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2916.webp","width":1080,"height":608,"caption":"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=32704#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Innovent Biologics Expands Clinical Partnership with ImmVirX to Include Hepatocellular Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/04\/2916.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=32704"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32704\/revisions"}],"predecessor-version":[{"id":32706,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/32704\/revisions\/32706"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/32705"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=32704"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=32704"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=32704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}